These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22410411)

  • 1. Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.
    Lamont EB; Lan L
    Med Care; 2014 Mar; 52(3):e15-20. PubMed ID: 22410411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
    Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA
    J Natl Cancer Inst; 2005 Jul; 97(14):1080-3. PubMed ID: 16030306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
    Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA;
    Med Care; 2008 Mar; 46(3):303-8. PubMed ID: 18388845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).
    Lamont EB; Yu M; He Y; Saltz L; Muss H; Zaslavsky AM;
    J Geriatr Oncol; 2014 Jul; 5(3):230-7. PubMed ID: 24594119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construct validity of medicare chemotherapy claims: the case of 5FU.
    Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
    Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
    Lamont EB; Herndon JE; Weeks JC; Henderson IC; Earle CC; Schilsky RL; Christakis NA;
    J Natl Cancer Inst; 2006 Sep; 98(18):1335-8. PubMed ID: 16985253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
    Duh MS; Reynolds Weiner J; Lefebvre P; Neary M; Skarin AT
    Curr Med Res Opin; 2008 Apr; 24(4):967-74. PubMed ID: 18282373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying specific chemotherapeutic agents in Medicare data: a validation study.
    Lund JL; Stürmer T; Harlan LC; Sanoff HK; Sandler RS; Brookhart MA; Warren JL
    Med Care; 2013 May; 51(5):e27-34. PubMed ID: 22080337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
    Lamont EB; Schilsky RL; He Y; Muss H; Cohen HJ; Hurria A; Meilleur A; Kindler HL; Venook A; Lilenbaum R; Niell H; Goldberg RM; Joffe S;
    J Natl Cancer Inst; 2015 Jan; 107(1):336. PubMed ID: 25432408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims.
    Kumamaru H; Judd SE; Curtis JR; Ramachandran R; Hardy NC; Rhodes JD; Safford MM; Kissela BM; Howard G; Jalbert JJ; Brott TG; Setoguchi S
    Circ Cardiovasc Qual Outcomes; 2014 Jul; 7(4):611-9. PubMed ID: 24963021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
    Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL
    Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
    Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Raab GT; Lin A; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Buono DL; Hur C; Kiran RP; Wright JD; Hershman DL; Neugut AI
    Clin Colorectal Cancer; 2019 Sep; 18(3):e294-e299. PubMed ID: 31266707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.
    Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
    Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data.
    Du X; Goodwin JS
    J Clin Oncol; 2001 Mar; 19(5):1455-61. PubMed ID: 11230491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ability of Medicare claims data to identify nursing home patients: a validation study.
    Koroukian SM; Xu F; Murray P
    Med Care; 2008 Nov; 46(11):1184-7. PubMed ID: 18953230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Neugut AI; Lin A; Raab GT; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Kiran RP; Wright J; Hershman DL
    Clin Colorectal Cancer; 2019 Jun; 18(2):133-140. PubMed ID: 30878317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.